Innovacell Biotechnologie AG

Innovacellis a privately-held phase III company engaged in the clin.dev. of autologous, minimally invasive, potentially curative cell therapies to re-establish functionality of sphincter muscle in patients with stress urinary incontinence (sui) or fecal incontinence.

  • Mitarbeiterzahl

    23
  • Ausrichtungen
    • Therapie-Entwickler
  • Gegründet

    2000
  • Aktualisiert am

    30.05.2018